PRASENJIT MITRA

Prasenjit Mitra's laboratory researches energy homeostasis. Presently located in India, the team explores incretin receptor signaling to ameliorate diabesity.

[PRASENJIT MITRA @PRASENJ77537655]

Reduced Incretin Receptor Trafficking upon Activation Enhances Glycemic Control and Reverses Obesity in Diet-Induce… https://t.co/0fADsTDpnY

[PRASENJIT MITRA @PRASENJ77537655]

@LykkeSylow @EmmaHeleneLars1 @tcppham Vesicles?

[PRASENJIT MITRA @PRASENJ77537655]

I-M-150847, a novel GLP-1 and GIP receptor dual agonist, reduces body weight gain and improves glycemic control in the rodent model of type 2 diabetes and obesity https://t.co/ATRcNGadyu

[PRASENJIT MITRA @PRASENJ77537655]

@SamLewisPhD I think that's the way to go.

[PRASENJIT MITRA @PRASENJ77537655]

I-M-150847, a novel GLP-1 and GIP receptor dual agonist, reduces body weight gain and improves glycemic control in the rodent model of type 2 diabetes and obesity https://t.co/ATRcNFS4km

[PRASENJIT MITRA @PRASENJ77537655]

@jalsasravan Shravan, the existing dogma is
A+B=AB where A= GLP-1, B= GIP ; AB= GLP1R GIPR dual agonist. The paradigm shift is A'+ B'=C.
A'=Ex-4, B' =Oxm C terminus (considered not useful)
C= GLP1R GIPR dual agonist. Pl comment on the paradigm shift

[PRASENJIT MITRA @PRASENJ77537655]

The concept can be expressed in a simple equation
A+ B=C
Where A= Ex-4 Y1;
B = Oxyntomodulin undecapeptide C terminus
C= GLP1R GIPR dual agonist.

We hope the readers will enjoy the “conceptual advance”.
Wishing all Merry Christmas and a very happy new year

[PRASENJIT MITRA @PRASENJ77537655]

I-M-150847, a novel GLP-1 and GIP receptor dual agonist, reduces body weight gain and improves glycemic control in the rodent model of type 2 diabetes and obesity https://t.co/ATRcNFS4km

[PRASENJIT MITRA @PRASENJ77537655]

@DanielJDrucker Dear Professor Drucker,
We appreciate your comments. Our objective was to dissect incretin receptor signaling at plasma membrane vis à vis endosome. I-M-150847 evokes cAMP signaling at the plasma membrane that regulates its insulinotropic property.
regards, Prasenjit